← Oncology Approval Tracker

FDA DECISION ·

Orencia

abatacept with a calcineurin inhibitor and methotrexate · Bristol Myers Squibb

FDA approvalNew or expanded indicationAcute graft-versus-host disease prevention
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Prophylaxis of acute graft-versus-host disease for patients age 2 and older undergoing hematopoietic stem cell transplantation from a matched or one-allele-mismatched unrelated donor.

LAMPGEN ANALYSIS

Why it matters

The label adds abatacept to a prophylactic regimen for a defined unrelated-donor transplant population.

What research teams should watch

Confirm donor match, transplant dates and concomitant prophylaxis, and follow post-transplant infection monitoring.

PRIMARY RECORDS

Sources